As a classic metabolic disease, renal cancer is characterized by the inactivation of the VHL gene and abnormal activation of the Ras-PI3K-AKT-mTOR pathway, leading to metabolic reprogramming that includes glutamine, tryptophan, and arginine metabolism, thereby promoting the occurrence and development of renal cancer [39]. This evidence concerns the gene AKT1 and metabolic disease.